1. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

   • Michelle N. Messmer
   • Colleen S. Netherby
   • Scott I. Abrams

   Review 29 November 2014 Pages: 1 - 13

   

2. Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment

   • Urban Švajger
   • Martina Gobec
   • Irena Mlinarič-Raščan

   Original Article 25 September 2014 Pages: 15 - 27

   

3. Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer

   • Leah J. Novinger
   • Takamaru Ashikaga
   • David N. Krag

   Original Article 27 September 2014 Pages: 29 - 39

   

4. Evaluation of complement proteins as screening markers for colorectal cancer

   • Line Storm
   • Ib J. Christensen
   • the Danish Study Group on Early Detection of Colorectal Cancer

   Original Article 27 September 2014 Pages: 41 - 50

   

5. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer

   • Hideki Kimura
   • Yukiko Matsui
   • Yuichi Sakairi

   Original Article Open access 28 September 2014 Pages: 51 - 59

   

6. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

   • Balaji Balasa
   • Rui Yun
   • Audie G. Rice

   Original Article Open access 07 October 2014 Pages: 61 - 73

   

7. Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

   • Snezana Zivancevic Simonovic
   • Olgica Mihaljevic
   • Ljiljana Mijatovic Teodorovic

   Original Article 09 October 2014 Pages: 75 - 82

   

8. Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies

   • Chiara Castelli
   • Licia Rivoltini
   • Paola Allavena

   Focussed Research Review 04 July 2014 Pages: 83 - 89

   

9. Cancer stem cells: perspectives for therapeutic targeting

   • Cristina Maccalli
   • Ruggero De Maria

   Focussed Research Review 08 August 2014 Pages: 91 - 97

   

10. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

    • Zlatko Trajanoski
    • Cristina Maccalli
    • Paolo Dellabona

    Focussed Research Review 28 August 2014 Pages: 99 - 104

11. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

    • Luana Calabrò
    • Giovanni Luca Ceresoli
    • Michele Maio

    Focussed Research Review 19 September 2014 Pages: 105 - 112

    

12. Armed antibodies for cancer treatment: a promising tool in a changing era

    • Riccardo Danielli
    • Roberto Patuzzo
    • Mario Santinami

    Focussed Research Review 15 October 2014 Pages: 113 - 121

    

13. Overcoming the toxicity hurdles of genetically targeted T cells

    • Monica Casucci
    • Robert E. Hawkins
    • Attilio Bondanza

    Focussed Research Review 09 December 2014 Pages: 123 - 130

    

14. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

    • Michele Maio
    • Hugues Jean Marie Nicolay
    • Giorgio Parmiani

    Meeting Report 04 July 2014 Pages: 131 - 135